AU2019315853B2 - Methods for treating neurodegenerative disorders - Google Patents

Methods for treating neurodegenerative disorders Download PDF

Info

Publication number
AU2019315853B2
AU2019315853B2 AU2019315853A AU2019315853A AU2019315853B2 AU 2019315853 B2 AU2019315853 B2 AU 2019315853B2 AU 2019315853 A AU2019315853 A AU 2019315853A AU 2019315853 A AU2019315853 A AU 2019315853A AU 2019315853 B2 AU2019315853 B2 AU 2019315853B2
Authority
AU
Australia
Prior art keywords
spa
subject
csf
tramiprosate
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019315853A
Other languages
English (en)
Other versions
AU2019315853A1 (en
Inventor
Neil William FLANZRAICH
John Hey
Petr Kocis
Martin TOLAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzheon Inc
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of AU2019315853A1 publication Critical patent/AU2019315853A1/en
Application granted granted Critical
Publication of AU2019315853B2 publication Critical patent/AU2019315853B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2019315853A 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders Active AU2019315853B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862713061P 2018-08-01 2018-08-01
US62/713,061 2018-08-01
PCT/US2019/044023 WO2020028290A1 (en) 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
AU2019315853A1 AU2019315853A1 (en) 2021-03-18
AU2019315853B2 true AU2019315853B2 (en) 2025-05-01

Family

ID=67614642

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019315853A Active AU2019315853B2 (en) 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders

Country Status (27)

Country Link
US (2) US12083082B2 (https=)
EP (1) EP3829563B1 (https=)
JP (1) JP7573512B2 (https=)
KR (1) KR102716959B1 (https=)
CN (1) CN112867485A (https=)
AU (1) AU2019315853B2 (https=)
BR (1) BR112021001739A2 (https=)
CL (1) CL2021000269A1 (https=)
DK (1) DK3829563T3 (https=)
EA (1) EA202190406A1 (https=)
ES (1) ES3011716T3 (https=)
FI (1) FI3829563T3 (https=)
HR (1) HRP20250206T1 (https=)
HU (1) HUE070101T2 (https=)
IL (1) IL280424B2 (https=)
LT (1) LT3829563T (https=)
MX (1) MX2021001287A (https=)
MY (1) MY206530A (https=)
PH (1) PH12021550213A1 (https=)
PL (1) PL3829563T3 (https=)
PT (1) PT3829563T (https=)
RS (1) RS66516B1 (https=)
SG (1) SG11202100767XA (https=)
SI (1) SI3829563T1 (https=)
SM (1) SMT202500080T1 (https=)
UA (1) UA130011C2 (https=)
WO (1) WO2020028290A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025504A2 (pt) * 2019-06-17 2022-04-26 Alzheon Inc Métodos para tratar distúrbios neurodegenerativos
MX2024007070A (es) * 2021-12-09 2024-08-22 Alzheon Inc Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028187A1 (en) * 1995-03-15 1996-09-19 Queen's University At Kingston Method for treating amyloidosis
WO2015143447A2 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
WO2017044840A1 (en) * 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
WO2013177367A2 (en) 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
WO2014121083A1 (en) 2013-01-31 2014-08-07 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028187A1 (en) * 1995-03-15 1996-09-19 Queen's University At Kingston Method for treating amyloidosis
WO2015143447A2 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
WO2017044840A1 (en) * 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHN A. HEY ET AL: "Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease", CLINICAL PHARMACOKINETICS., 2017, vol. 57, no. 3, pages 315 - 333 *
S ABUSHAKRA ET AL: "Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential", THE JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE, 2017, pages 149 - 156, *

Also Published As

Publication number Publication date
PH12021550213A1 (en) 2021-11-03
CA3108150A1 (en) 2020-02-06
US12083082B2 (en) 2024-09-10
KR102716959B1 (ko) 2024-10-11
CN112867485A (zh) 2021-05-28
FI3829563T3 (fi) 2025-02-17
EA202190406A1 (ru) 2021-10-15
MX2021001287A (es) 2021-07-15
JP2021533128A (ja) 2021-12-02
PT3829563T (pt) 2025-02-18
US20210315847A1 (en) 2021-10-14
SG11202100767XA (en) 2021-02-25
HUE070101T2 (hu) 2025-05-28
IL280424A (en) 2021-03-01
US20250213507A1 (en) 2025-07-03
KR20210039415A (ko) 2021-04-09
MY206530A (en) 2024-12-19
CL2021000269A1 (es) 2021-06-18
SI3829563T1 (sl) 2025-05-30
ES3011716T3 (en) 2025-04-08
EP3829563B1 (en) 2024-11-20
UA130011C2 (uk) 2025-10-15
BR112021001739A2 (pt) 2021-04-27
IL280424B1 (en) 2024-09-01
RS66516B1 (sr) 2025-03-31
IL280424B2 (en) 2025-01-01
HRP20250206T1 (hr) 2025-04-11
PL3829563T3 (pl) 2025-04-07
AU2019315853A1 (en) 2021-03-18
WO2020028290A1 (en) 2020-02-06
DK3829563T3 (en) 2025-02-24
LT3829563T (lt) 2025-02-25
EP3829563A1 (en) 2021-06-09
JP7573512B2 (ja) 2024-10-25
SMT202500080T1 (it) 2025-03-12

Similar Documents

Publication Publication Date Title
US20250213507A1 (en) Methods for treating neurodegenerative disorders
US20260034088A1 (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
CA3108150C (en) Methods for treating neurodegenerative disorders
HK40056250B (en) 3-sulfopropanoic acid for treating neurodegenerative disorders
HK40056250A (en) 3-sulfopropanoic acid for treating neurodegenerative disorders
EA048644B1 (ru) Способы лечения нейродегенеративных расстройств
HK40105684B (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
HK40105684A (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
HK40056251B (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
HK40056251A (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
EA052917B1 (ru) Способы лечения нейродегенеративных расстройств

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)